secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2022-01-26T23:59:59+00:00
Accession:  0001193125-22-017680
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology appoints Richard Wooster to board of directors; board increases to 8
--------------------------------------------------------------------------------

- Richard Wooster, Ph.D., appointed to fill new vacancy, effective Jan. 21, 2022; board expands from 7 to 8.
- Wooster qualifies as independent director; receives option for 29,200 shares vesting over 3 years.
- He brings 30+ years oncology drug discovery experience; discovered BRCA2 gene, co-discovered BRAF mutations.
- Most recently CSO at Translate Bio (acquired by Sanofi 2021); previously VP at GSK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312522017680/0001193125-22-017680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312522017680/d252798d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-017680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer